

STRICTLY PRIVATE & CONFIDENTIAL

21 November 2024

**LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.**

Room 201, Building 41  
No. 258, Xinzhuan Road  
Songjiang District, Shanghai  
China

**Attention: The Board of Directors**

Dear Sir/Madam,

**RENEWAL OF THE CONTINUING CONNECTED TRANSACTIONS  
IN RELATION TO THE ENTRUSTED PRODUCTS  
RELATED FRAMEWORK AGREEMENT**


We refer to the circular of LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. dated 21 November 2024 (the “**Circular**”) in respect of the captioned matter. Unless otherwise defined herein, terms used in this letter shall have the same meanings as defined in the Circular.

We hereby consent and confirm that we have not withdrawn our written consent to the issue of the Circular with the inclusion therein of our letter dated 21 November 2024 (the “**IFA Letter**”) and the references to our name and our letter in the form and context in which they appear.

We further consent to the IFA Letter and this letter being made available for public display as described in the section headed “9. DOCUMENTS AVAILABLE ON DISPLAY” in APPENDIX – GENERAL INFORMATION to the Circular.

Except as stated above, our said letter is not to be quoted or referred to, in whole or in part, nor shall our said letter or this consent letter be used for any other purpose, without our prior written consent.

Yours faithfully,  
For and on behalf  
**Orient Capital (Hong Kong) Limited**



---

**Edmund Wong**  
Managing Director